Featured Research

from universities, journals, and other organizations

Breast Cancer Prognosis: Response To Preventive HER2/neu Peptide (E75) Vaccine Based On HER2/neu Status

Date:
April 13, 2008
Source:
American Association for Cancer Research
Summary:
A HER2 peptide E75 vaccine reduced mortality in patients with HER2-positive breast cancer by half, according to Texas researchers. In particular, patients with low-expressing HER2 tumors exhibited better response, not only immunologically, but clinically, with decreased breast cancer recurrence and no mortality following vaccination, report researchers.

A HER2 peptide E75 vaccine reduced mortality in patients with HER2-positive breast cancer by half, according to Texas researchers.

Related Articles


In particular, patients with low-expressing HER2 tumors exhibited better response, not only immunologically, but clinically, with decreased breast cancer recurrence and no mortality following vaccination, report researchers from Brooke Army Medical Center in San Antonio, Texas.

"The fact that HER2 low-expressors responded so favorably not only underscores the difference in mechanism between the vaccine vs. antibody therapy like trastuzumab, but also offers the hope of additional adjuvant therapy to the largest subset of breast cancer patients if proven in the upcoming phase III trial," said Linda C. Benavides, M.D., a resident in general surgery at Brooke Army Medical Center.

HER2, a source of immunogenic peptides, is over-expressed in approximately 25 to 30 percent of patients with early stage breast cancer.

The CVDP has conducted clinical trials with the HER2 E75-peptide vaccine in lymph node--positive and lymph node--negative patients with breast cancer who demonstrated varying levels of HER2 expression.

They conducted a subset analysis of 163 patients with breast cancer enrolled in the E75 vaccine trial to determine whether the level of HER2 expression affected vaccine response. Of 163 patients assessed, 92 underwent vaccination. Within the vaccinated treatment arm, 29 (34 percent) were defined as HER2 over-expressors, and 56 (66 percent) were defined as low-expressors. The 71 patients in the control group included 22 (33 percent) over-expressors and 44 (67 percent) low-expressors. Patients over-expressing HER2 were similar with regard to prognostic and treatment factors, except that a statistically larger number of vaccinated over-expressors had hormone receptor--negative tumors (P = 0.02).

Following vaccination, immunologic responses were similar as measured by delayed-type hypersensitivity reaction; however, patients in the vaccination arm who were low-expressors of HER2 demonstrated an increased number of E75-specific CD8+ T cells when compared with the vaccinated over-expressors.

At a median follow-up of 30 months, disease recurrence rates were similar between HER2 over-expressors in both the vaccine and control groups, with recurrence rates of 18.2 percent and 13.8 percent, respectively. Although these recurrence rates were comparable (P = 0.7), the researchers observed a greater than 50 percent reduction in mortality rate among patients whose disease recurred.

Interestingly, recurrence was more substantially reduced for vaccinated patients with low HER2 expression, Benavides says. Vaccinated low-expressors experienced 10.7 percent recurrence, compared with 18.2 percent for participants in the control group. Furthermore, the mortality rate among low-expressors with recurrent disease was 0 percent among vaccinated patients, versus 38 percent among the control group (P=0.08). Taken together these findings may be significant for the greater than 50 percent of breast cancer patients whose tumors fall into the HER2 low-expressing category and who are not eligible for trastuzumab treatment, Benavides concludes.

This research was presented at the American Association for Cancer Research 2008 Annual Meeting, April 12-16.


Story Source:

The above story is based on materials provided by American Association for Cancer Research. Note: Materials may be edited for content and length.


Cite This Page:

American Association for Cancer Research. "Breast Cancer Prognosis: Response To Preventive HER2/neu Peptide (E75) Vaccine Based On HER2/neu Status." ScienceDaily. ScienceDaily, 13 April 2008. <www.sciencedaily.com/releases/2008/04/080413163559.htm>.
American Association for Cancer Research. (2008, April 13). Breast Cancer Prognosis: Response To Preventive HER2/neu Peptide (E75) Vaccine Based On HER2/neu Status. ScienceDaily. Retrieved November 26, 2014 from www.sciencedaily.com/releases/2008/04/080413163559.htm
American Association for Cancer Research. "Breast Cancer Prognosis: Response To Preventive HER2/neu Peptide (E75) Vaccine Based On HER2/neu Status." ScienceDaily. www.sciencedaily.com/releases/2008/04/080413163559.htm (accessed November 26, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Wednesday, November 26, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

From Popcorn To Vending Snacks: FDA Ups Calorie Count Rules

From Popcorn To Vending Snacks: FDA Ups Calorie Count Rules

Newsy (Nov. 25, 2014) — The US FDA is announcing new calorie rules on Tuesday that will require everywhere from theaters to vending machines to include calorie counts. Video provided by Newsy
Powered by NewsLook.com
Daily Serving Of Yogurt Could Reduce Risk Of Type 2 Diabetes

Daily Serving Of Yogurt Could Reduce Risk Of Type 2 Diabetes

Newsy (Nov. 25, 2014) — Need another reason to eat yogurt every day? Researchers now say it could reduce a person's risk of developing type 2 diabetes. Video provided by Newsy
Powered by NewsLook.com
Madagascar Working to Contain Plague Outbreak

Madagascar Working to Contain Plague Outbreak

AFP (Nov. 24, 2014) — Madagascar said Monday it is trying to contain an outbreak of plague -- similar to the Black Death that swept Medieval Europe -- that has killed 40 people and is spreading to the capital Antananarivo. Duration: 00:42 Video provided by AFP
Powered by NewsLook.com
Are Female Bosses More Likely To Be Depressed?

Are Female Bosses More Likely To Be Depressed?

Newsy (Nov. 24, 2014) — A new study links greater authority with increased depressive symptoms among women in the workplace. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins